Effectiveness of the glycoprotein IIb/IIIa antagonist abciximab during percutaneous coronary interventions (PCI) in clinical practice at a single high-volume center

Zeitschrift fur Kardiologie

Volumn 92, Issue 6, 2003, Pages 438-444

  Zahn, Ralf ^a   Fraiture, Boris ^a   Siegler, Karl Ernst ^a   Schneider, Steffen ^a   Gitt, Anselm K ^a   Seidl, Karlheinz ^a   Gandjour, Afschin ^b   Wendland, Guido ^b   Vogt, Albrecht ^c   Lauterbach, Karl Wilhelm ^b   Senges, Jochen ^a  

^a KLINIKUM LUDWIGSHAFEN   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c KLINIKUM KASSEL   (Germany)

Author keywords

Abciximab; Clinical practice; Coronary angioplasty; Glycoprotein IIb IIIa antagonist

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN RECEPTOR ANTAGONIST; PHENPROCOUMON; STATINE DERIVATIVE; TICLOPIDINE;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CLINICAL PRACTICE; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY OBSTRUCTION; DRUG EFFICACY; FEMALE; HEART DEATH; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE ISCHEMIA; HOSPITALIZATION; HUMAN; INTERVENTIONAL RADIOLOGY; MAJOR CLINICAL STUDY; MALE; STROKE; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

EID: 0037803453     PISSN: 03005860     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00392-003-0928-1     Document Type: Article

References (23)

1. Anderson KM, Califf RM, Stone GW, Neumann FJ, Montalescot G, Miller DP, Ferguson JJ III, Willerson JT, Weisman HF, Topol EJ (2001) Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol 37:2059-2065
2. Brener SJ, Barr LA, Burchenal JE, Katz S, George BS, Jones AA, Cohen ED, Gainey PC, White HJ, Cheek HB et al (1998) Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation 98:734-741
3. Frilling B, Zahn R, Fraiture B, Mark B, Dönges K, Becker T, Siegler KE, Seidl K, Rustige J, Senges J (2002) Comparison of efficacy and complication rates after percutaneous coronary interventions in patients with and without renal insufficiency treated with abciximab. Am J Cardiol 89:450-452
4. Fuchs S, Kornowski R, Mehran R, Gruberg L, Satler LF, Pichard AD, Kent KM, Stone GW, Leon MB (2000) Clinical outcomes following "rescue" administration of abciximab in patients undergoing percutaneous coronary angioplasty. J Invasive Cardiol 12:497-501
5. Haase KK, Mahrholdt H, Schroder S, Baumbach A, Oberhoff M, Herdeg C, Karsch KR (1999) Frequency and efficacy of glycoprotein IIb/IIIa therapy for treatment of threatened or acute vessel closure in 1332 patients undergoing percutaneous transluminal coronary angioplasty. Am Heart J 137:234-240
6. Kandzari DE, Tcheng JE, Harrington RA, Sketch MH Jr (2000) "Rescue" platelet GP IIb/IIIa inhibitor therapy in percutaneous coronary intervention: bailing out of a sunken ship. J Invasive Cardiol 12:502-504
7. Kereiakes DJ, Obenchain RL, Barber BL, Smith A, McDonald M, Broderick TM, Runyon JP, Shimshak TM, Schneider JF, Hattemer CR et al (2000) Abciximab provides cost-effective survival advantage in high-volume interventional practice. Am Heart J 140:603-610
8. Lincoff AM, Mark DB, Tcheng JE, Califf RM, Bala MV, Anderson KM, Davidson-Ray L, Knight JD, Cabot CF, Topol EJ (2000) Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade with abciximab and low-dose heparin during percutaneous coronary revascularization: results from the EPILOG randomized trial. Evaluation in PTCA to improve long-term outcome with abciximab GP IIb/IIIa blockade. Circulation 102:2923-2929
9. Mark DB, Talley JD, Topol EJ, Bowman L, Lam LC, Anderson KM, Jollis JG, Cleman MW, Lee KL, Aversano T et al (1996) Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC Investigators. Circulation 94:629-635
10. Reed SO, Mullins CD, Magder LS (2000) Cost effectiveness of abciximab during routine medical practice. Pharmacoeconomics 18:265-274
11. Roffi M, Chew DP, Mukherjee D, Bhatt DL, White JA, Heeschen C, Hamm CW, Moliterno DJ, Califf RM, White HD et al (2001) Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation 104:2767-2771
12. The CAPTURE Investigators (1997) Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 349:1429-1435
13. The EPIC Investigatiors (1994) Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 330:956-961
14. The EPILOG Investigators (1997) Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 336:1689-1696
15. The EPISTENT Investigators (1998) Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 352:87-92
16. The ESPRIT Investigators (2000) Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 356:2037-2044
17. The PRISM-PLUS Study Investigators (1998) Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med 338:1488-1497
18. The PRISM Investigators (1998) A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. N Engl J Med 338:1498-1505
19. Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, Ivanhoe R, George BS, Fintel D, Weston M et al (1994) Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators. Lancet 343:881-886
20. Topol EJ, Mark DB, Lincoff AM, Cohen E, Burton J, Kleiman N, Talley D, Sapp S, Booth J, Cabot CF et al (1999) Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 354:2019-2024
21. Topol EJ, Moliterno DJ, Herrmann HC, Powers ER, Grines CL, Cohen DJ, Cohen EA, Bertrand M, Neumann FJ, Stone GW et al (2001) Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 344:1888-1894
22. Vogt A, Bonzel T, Harmjanz D, von Leitner ER, Pfafferott C, Engel HJ, Niederer W, Schuster PR, Glunz HG, Neuhaus KL (1997) PTCA registry of German community hospitals. Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK) Study Group. Eur Heart J 18:1110-1114
23. Weintraub WS (2001) Economics of coronary stenting and GPIIb/IIIa blockade. Eur Heart J 22:1366-1368